384 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi
6-K
EX-99.3
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions
6-K
EX-99.1
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
, including 12 phase 3 data readouts
Corporate Social Responsibility progress
Sanofi Global Health Unit: making a difference for patients in low … , and with no concession of liability. This resolution is not anticipated to have any material financial impact.
Corporate Social Responsibility update
6-K
EX-99.1
9hk8w7o3j5 5un1gsne
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
EX-99.1
5w1s7h
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.4
h0kbo2kmzx4k60pcsh8
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.2
piw 8bvhv
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.3
cdw0h67sgkcqkt02i1
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
yaqyk 5ygpxzcze8nc
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
9s4eszsonryriml
15 Feb 24
Current report (foreign)
12:09pm
6-K
EX-99.1
ypwznh
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.2
aew6jti3m y5j
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
koiskbk384d
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
jrn3vzafnyah7ugjzdba
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
y1ki9
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
EX-99.1
pvh8nc5up8guqx6s
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.4
1nw040
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.3
xjb2dq49ij8 y9eq4
20 Dec 23
Current report (foreign)
10:39am